Epigenomics AG: Epigenomics adjusts 2015 outlook after FDA response letter

Epigenomics AG  / Key word(s): Miscellaneous

04.11.2015 20:30

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Epigenomics adjusts 2015 outlook after FDA response letter

Berlin, Germany, November 4, 2015 - Epigenomics AG, Berlin, Germany,
(Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) adjusts its financial
outlook for fiscal year 2015 following the FDA response letter on the
Company's lead product Epi proColon(R). As communicated in the past, such a
decision has a significant impact on the achievement of certain projected
financial parameters for 2015.

The Company's financial outlook for 2015 changes as follows:

Revenue is projected to exceed last year's figure of EUR 1.5 million, which
is significantly less than the projected EUR 3-4 million. In the first nine
months 2015, Epigenomics recorded revenue of EUR 1.3 million* (9M 2014: EUR
1.1 million).

EBIT is now projected at the lower end, or may slightly fall short, of the
previous outlook range of EUR -10.0 to -11.0 million. Cash consumption is
projected at the upper end of, or may slightly exceed, the previous outlook
range of EUR 9.5 to 10.5 million.

*preliminary; final report on first nine months of 2015 will be published
on November 18, 2015

- End of Ad hoc -

Contact Epigenomics AG

Peter Vogt, Investor & Public Relations
Epigenomics AG
Geneststraße 5
10829 Berlin
Phone +49 (0) 30 24345 386
ir@epigenomics.com

www.epigenomics.com

Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements
involve certain known and unknown risks, uncertainties and other factors
which could cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Epigenomics AG is providing this communication
as of this date and does not undertake to update any forward-looking
statements contained herein as a result of new information, future events
or otherwise.

The information contained in this communication does not constitute nor
imply an offer to sell or transfer any product, and no product based on
this technology is currently available for sale by Epigenomics in the
United States or Canada. The analytical and clinical performance
characteristics of any Epigenomics product based on this technology which
may be sold at some future time in the U.S. have not been established.


04.11.2015 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Epigenomics AG
              Geneststraße 5
              10829 Berlin
              Germany
Phone:        +49 30 24345-0
Fax:          +49 30 24345-555
E-mail:       ir@epigenomics.com
Internet:     www.epigenomics.com
ISIN:         DE000A11QW50
WKN:          A11QW5
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated
              Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------